CSL Seqirus to supply UK with AUJEMFLU flu shot from 2027/28 season
CSL unit Seqirus has secured a UK rollout of its adjuvanted cell-based flu vaccine AUJEMFLU starting in the 2027/28 season. UKHSA has extended its pandemic Advance Purchase Agreement with Seqirus through 2031, supporting influenza outbreak readiness. The deal includes an option for the UK to buy more than 100 million doses of pandemic influenza vaccine if WHO declares a flu pandemic. Seqirus will continue supplying its adjuvanted egg-based flu vaccine for the 2026/27 UK season.
Story updates
11:03:00 PM UTC
SquawkNews
CSL’s Seqirus unit strengthened its partnership with the UK government, adding AUJEMFLU to the national flu program from 2027/28. UKHSA extended its pandemic Advance Purchase Agreement with Seqirus by four years to 2031, anchored by vaccine manufacturing in Liverpool. Renewed APA gives the UK an option to buy more than 100 million pandemic influenza doses if the WHO declares a flu pandemic. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via (Ref. ID: EN53102) on September 21, 2026, and is solely responsible for the information contained therein. (C)